NewSquare Capital LLC Has $1.06 Million Stake in Gilead Sciences, Inc. (GILD)
NewSquare Capital LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,851 shares of the biopharmaceutical company’s stock after purchasing an additional 1,443 shares during the quarter. NewSquare Capital LLC’s holdings in Gilead Sciences were worth $1,064,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Welch Investments LLC acquired a new stake in Gilead Sciences in the 3rd quarter valued at $108,000. Wealthcare Advisory Partners LLC acquired a new stake in Gilead Sciences in the 3rd quarter valued at $133,000. Horan Capital Advisors LLC. acquired a new stake in Gilead Sciences in the 3rd quarter valued at $144,000. Hanson & Doremus Investment Management grew its stake in Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 1,613 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Gilead Sciences in the 2nd quarter valued at $147,000. 76.97% of the stock is currently owned by institutional investors and hedge funds.
In other news, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $73.87, for a total transaction of $1,108,050.00. Following the transaction, the executive vice president now owns 64,613 shares in the company, valued at approximately $4,772,962.31. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Robin L. Washington sold 5,000 shares of Gilead Sciences stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total value of $401,550.00. Following the transaction, the chief financial officer now owns 23,749 shares in the company, valued at approximately $1,907,282.19. The disclosure for this sale can be found here. In the last quarter, insiders have sold 349,435 shares of company stock worth $27,702,580. Insiders own 1.30% of the company’s stock.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The business had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. During the same quarter in the previous year, the firm earned $2.70 EPS. The company’s quarterly revenue was down 18.7% compared to the same quarter last year. research analysts expect that Gilead Sciences, Inc. will post 6.21 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 2.90%. The ex-dividend date of this dividend is Thursday, March 15th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is currently 59.77%.
A number of research firms recently issued reports on GILD. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price target on the stock in a research note on Monday, February 5th. Leerink Swann dropped their price target on shares of Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 7th. Citigroup reissued a “buy” rating and issued a $105.00 price target (up previously from $103.00) on shares of Gilead Sciences in a research note on Thursday, February 8th. BMO Capital Markets lifted their price target on shares of Gilead Sciences from $86.00 to $88.00 and gave the company a “market perform” rating in a research note on Thursday, February 8th. Finally, Mizuho lifted their price target on shares of Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $86.92.
TRADEMARK VIOLATION NOTICE: This story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/newsquare-capital-llc-has-1-06-million-stake-in-gilead-sciences-inc-gild/1908756.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.